Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EXCRETION Clear all
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Metabolic Surgery for Atrial Fibrillation Elimination

NCT07027969
View directory record Official record
Conditions
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Food Allergen Eliminations and Combined Protocols for Obesity Reduction: a Preliminary Comparison Study

NCT03821818
View directory record Official record
Conditions
Obesity
Interventions
Food Allergy Elimination + Willis Exercise
Behavioral
Lead sponsor
Galveston Clinical Research Foundation
Other
Eligibility
20 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 19, 2026, 5:57 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

NCT01275781
View directory record Official record
Conditions
Healthy
Interventions
[14C]-AZD9742
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803

NCT05286281
View directory record Official record
Conditions
Healthy
Interventions
PF-07265803
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Partnership for Rapid Elimination of Trachoma

NCT00792922
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 5 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

NCT03703505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-348, [13C6]AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 19, 2026, 5:57 PM EDT
Not listed No phase listed Observational

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

NCT06259331
View directory record Official record
Conditions
Healthy Lactating Women
Interventions
SPN-812 (600mg, QD)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

NCT02475317
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Maralixibat, Volixibat
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

NCT06826989
View directory record Official record
Conditions
Healthy
Interventions
[14C]MK-8527
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

NCT00472368
View directory record Official record
Conditions
Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Study of Renal Denervation in Patients With Heart Failure

NCT01954160
View directory record Official record
Conditions
Heart Failure
Interventions
Symplicity Renal Denervation
Device
Lead sponsor
Adrian Hernandez
Other
Eligibility
21 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD0914 Phase 1 ADME Study in Healthy Volunteers

NCT02298920
View directory record Official record
Conditions
Healthy
Interventions
AZD0914
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects

NCT01474668
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0941
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

NCT03104517
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
AMDC-USR (iltamiocel), Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

NCT02489513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-AG-120
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

NCT05974046
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
[14C]IDV184001AN
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Not applicable Interventional

Effect of Personalized Elimination Diet on Food Sensitivity Related Symptoms

NCT05389683
View directory record Official record
Conditions
Food Sensitivity
Interventions
Elimination Diet
Behavioral
Lead sponsor
Vibrant America Clinical Lab
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Gilbert, Arizona • Scottsdale, Arizona • San Carlos, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

NCT02054572
View directory record Official record
Conditions
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Interventions
[¹⁴C]Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational

3D Ultrasound in Women With Vacuum or Forceps Deliveries

NCT01680731
View directory record Official record
Conditions
Pelvic Floor Injury, Urinary Incontinence, Stool Incontinence
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration

NCT04397445
View directory record Official record
Conditions
Ranitidine Adverse Reaction, Pharmacokinetics, Food-drug Interaction
Interventions
Ranitidine, Placebo, Low nitrite/NDMA meals, High nitrite/NDMA meals
Drug · Other
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 19, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

NCT05776277
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Iltamiocel, Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
La Jolla, California • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Not yet recruiting Phase 1 Interventional

Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

NCT07790575
View directory record Official record
Conditions
Cytopenia
Interventions
AZD0120, Bendamustin
Drug
Lead sponsor
Saurabh Dahiya
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 5:57 PM EDT